According to preclinical research published in Cell, researchers with City of Hope discovered that a type of human immune cells known to be important for allergy and other immune responses—human type 2 innate lymphoid cells, or ILC2s—can also attack cancer.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
